Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Allogene Therapeutics Inc

ALLO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.05

▲ +3.54%

Market Cap $708.26M · Vol 969.65K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$708.26M

Small Cap

Div Yield

N/A

EPS Growth

+23.83%

YoY

RSI (14)

64.71

Momentum

Beta

0.49

vs Market

52W High

$4.46

54.04% below

52W Low

$1.03

99.03% above

Volume

969.65K

Avg 1.41M

P/B

1.07

Price-to-book

ROE

-53.42%

Return on equity

Free Float

76.53%

Public shares

Shariah Compliance8 STANDARDS

✗ Allogene Therapeutics Inc (ALLO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALLO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.99%

+10.81%

-4.21%

+13.89%

YTD

+49.64%

+91.59%

-49.75%

-90.44%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-190,886,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-53.42%
ROA · ROIC	-39.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.07
P/FCF	N/A
EPS Growth	+23.83%
Outstanding Shares	345.49M

Technical Indicators

50-Day SMA	$1.95
200-Day SMA	$1.90
RSI (14)	64.71
Beta	0.49
52-Week High	$4.46
52-Week Low	$1.03

Volume Today	969.65K
Avg Daily Volume (30D)	1.41M
Relative Volume	0.69x
Volatility (10D)	43.84
Volatility (30D)	60.22
Free Float	76.53%

Analyst Consensus

BUY

Current Price $2.05

Mean Target $9.00

52W Low$1.03 52W High$4.46

Current

Target

$1.03 $4.46

Current Analyst target

+339.02% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00KHRRDY2

ISINUS0197701065

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.